N@N

DALLAS--([ BUSINESS WIRE ])--Former United States Securities and Exchange Commission attorney [ Willie Briscoe ], founder of [ The Briscoe Law Firm, PLLC ], and the securities litigation firm of [ Powers Taylor, LLP ] announce that the firms are investigating legal claims against the officers and Board of [ ViroPharma Incorporated ] (aViroPharmaa) (NASDAQ: VPHM) related to potential securities violations by ViroPharma between December 14, 2011 and April 9, 2012 (the aClass Perioda).

If you are an affected investor and you want to learn more about the lawsuit or join the action, contact Patrick Powers at Powers Taylor, LLP, toll free (877) 728-9607, via e-mail at [ patrick@powerstaylor.com ], or Willie Briscoe at The Briscoe Law Firm, PLLC, (214) 706-9314, or via email at [ WBriscoe@TheBriscoeLawFirm.com ]. There is no cost or fee to you.

In a recently filed class action lawsuit, ViroPharma and certain of its officers and directors were charged with violating certain provisions of the Securities Exchange Act of 1934. Notably, the complaint alleges that defendantsa misrepresented and/or failed to disclose that (1) ViroPharma had no basis for its stated belief that a new supplemental drug application ("sNDA") approval for Vancocin would qualify for three additional years of exclusivity; and (2) generic Vancomycin capsules would not be approved during that time. However, on April 10, 2012, ViroPharma announced that the sNDA approval would not qualify for three additional years of exclusivity, and that the FDA indicated that it was approving three applications for generic Vancomycin capsules. As a result of the announcement, ViroPharma shares dropped by 22%.

[ The Briscoe Law Firm, PLLC ] is a full service business litigation, commercial transaction, and public advocacy firm with more than 20 years of experience in complex litigation and transactional matters.

[ Powers Taylor, LLP ] is a boutique litigation law firm that handles a variety of complex business litigation matters, including claims of investor and stockholder fraud, shareholder oppression, shareholder derivative suits, and security class actions.